Business Wire

TX-MARY-KAY

Share
Mary Kay Inc. & European Society for Dermatological Research Partner to Award Educational Research Grants Advancing Skin Health/Skin Disease

Mary Kay Inc., a global leader in skin care innovation, in partnership with the European Society for Dermatological Research, recently announced its inaugural Mary Kay Skin Health/Skin Disease Research Grant awardees at a special virtual event prior to the First International Societies for Investigative Dermatology conference in May. Grant recipients are researchers conducting groundbreaking, innovative studies in skin health and skin disease.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230517005040/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Mary Kay partnered with European Society for Dermatological Research (ESDR) to award inaugural Mary Kay-ESDR Skin Health/Skin Disease Research Grants. Congratulations to our 2022 recipients, Dr. Clarisse Ganier and Dr. Michael Cangkrama, who will each receive $20,000 grants to further their contributions in skin disease research. (Photo: Mary Kay Inc.)

“Mary Kay is dedicated to advancing skin and nutritional health research globally, and we know this cannot be done alone. Collaboration across industries, academic institutions, and clinicians is critical, which is why we are proud to partner with ESDR to furnish the first-ever Mary Kay-ESDR Skin Health/Skin Disease Research Grants,” said Dr. Lucy Gildea, Chief Innovation Officer, Product and Science at Mary Kay. “These grants bring this larger community together for new inspiration for the future, and Mary Kay is proud to be a part of this opportunity. We are excited to see how these recipients bring greater advancements to different aspects of skin health research.”

The Mary Kay Skin Health/Skin Disease Research Grants were announced at last year’s meeting in partnership with ESDR. The $20,000 grants were to be awarded to two researchers conducting incredible work in skin research to uncover new perspectives and invention strategies. In the months following the 2022 ESDR meeting, the company received applications from scientists across all of Europe.

The two grant awardees ultimately selected were:

  • Dr. Michael Cangkrama, (Switzerland) Senior Scientist, Department of Biology, Institute of Molecular Health Sciences, ETH Zürich – Dr. Cangkrama is working on molecular and cellular mechanisms underlying the development and progression of epithelial skin cancers, the most common types of cancer in humans. His research projects will focus on investigating molecular mechanisms of squamous cancer development and the role of the tumor microenvironment using state-of-the-art approaches. He will utilize the grant to further develop his independent projects and continue to pursue positions as an independent group leader or Assistant Professor in Europe.
  • Dr. Clarisse Ganier, (United Kingdom), Research Associate at the Center of Gene Therapy and Regenerative Medicine in King’s College London. Dr. Ganier is part of the Human Cell Atlas initiative – an international collaborative effort to map all cell types within the human body – to generate a comprehensive Skin Cell Atlas. As part of this work, they have created a multi-scale spatial atlas of healthy skin and basal cell carcinoma (BCC), incorporating single cell transcriptomics, in vivo optical coherence tomography, spatial global transcriptional profiling and in situ sequencing. Funding for this research will allow her to pursue her professional goals of starting her own laboratory focusing on skin cancer biology by combining multiomics data, both in vitro and ex vivo.

“Congratulations to each of our 2022 grant award recipients,” added Dr. Gildea. “These individuals were carefully chosen in collaboration with the European Society for Dermatological Research—and we are thrilled to support their research.”

“On behalf of the ESDR board, we would like to thank Mary Kay for its support of the ESDR and congratulate this year’s grant recipients for their tremendous contributions to their respective fields. A key objective of our Society is to promote innovative research in investigative dermatology and to support researchers' activities in translational skin research,” said Eli Sprecher, Chair, Scientific Program Committee of ESDR.

The sponsorship and grants, revealed leading up to the inaugural International Societies for Investigative Dermatology Conference in Tokyo, are just the latest efforts by Mary Kay to reinforce the company’s long-standing commitment to advancing skin health research and development. Mary Kay holds more than 1,600 patents for products, technologies and packaging designs in its global portfolio.

View the full Mary Kay-ESDR Skin Health/Skin Disease Research Grants Ceremony recording here.

About Mary Kay

One of the original glass ceiling breakers, Mary Kay Ash founded her dream beauty company in 1963 with one goal: enriching women’s lives. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in more than 35 countries. As an entrepreneurship development company, Mary Kay is committed to empowering women on their journey to economic independence through education, mentorship, advocacy, networking, and innovation. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skincare, color cosmetics, nutritional supplements, and fragrances. Mary Kay believes in enriching lives today for a sustainable tomorrow, partnering with organizations from around the world focusing on promoting business excellence, supporting cancer research, advancing gender equality, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Learn more at marykayglobal.com, find us on Facebook, Instagram, and LinkedIn or follow us on Twitter.

About European Society for Dermatological Research (ESDR)

The European Society for Dermatological Research (ESDR), founded in 1970, is a non-profit organization promoting basic and clinical science related to dermatology. The ESDR is the largest investigative dermatology society in Europe with a current membership of about 1100. By supporting investigative dermatology and skin research, the ESDR contributes to an in-depth understanding of skin homeostasis and toward improving the health of patients suffering from skin and venereal diseases. The ESDR facilitates the exchange of information relevant to investigative dermatology between clinicians and scientists worldwide. The ESDR also organizes educational events throughout the year to further knowledge in dermatological research. For more information, please visit: https://esdr.org/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230517005040/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

1X Announces Strategic Partnership to Make up to 10,000 Humanoid Robots Available to EQT’s Global Portfolio11.12.2025 15:00:00 CET | Press release

1X, the AI and robotics company behind NEO, the first ready-to-ship humanoid robot, today announced a strategic partnership with EQT, one of the world’s largest private equity firms and an investor in 1X through EQT Ventures. The partnership marks the beginning of what could become a large-scale commercial rollout of general-purpose humanoid robots across multiple industries. Together, 1X and EQT have a shared intent to facilitate the rollout of up to 10,000 humanoids across EQT’s global portfolio companies between 2026 and 2030, with any potential implementation decision ultimately taken by each portfolio company. The partnership represents an early step in bringing humanoid robotics into mainstream commercial use. Through this collaboration, EQT’s portfolio companies will gain early access to 1X’s commercial production capacity and integration expertise, giving early adopters a first-mover advantage in addressing structural workforce transformation. The partnership will focus on high

Texas Card House to Host World Series of Poker® Circuit in 202611.12.2025 15:00:00 CET | Press release

Exclusive partnership brings the World Series of Poker to Texas for the first time. The World Series of Poker (WSOP) has announced that Texas will join its exclusive ranks as an official stop on the 2026 Circuit Tour for the first time in history. Through an exclusive partnership with Texas Card House, the iconic WSOP Circuit will be hosted in Austin, at TCH Social from April 23rd to May 4th 2026. TCH Social is one of the Texas-based company’s flagship locations featuring up to 70 poker tables, a full-service restaurant, craft cocktails, and an upscale atmosphere. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251211428594/en/ Texas Card House Social Austin, the first-ever Texas venue to welcome the WSOP Circuit. During the event, Texas will become the center of the professional poker universe. Players from around the world will compete at the Texas Card House in Austin to claim a championship WSOP Circuit ring, enormous pri

Nexo Acquires Buenbit in Major Expansion Across Latin America11.12.2025 15:00:00 CET | Press release

The acquisition combines Nexo’s comprehensive award-winning product portfolio with Buenbit’s CNV-registered operations and strong local expertise.Global digital assets leader Nexo establishes Buenos Aires as its Latin American hub, supporting long-term investment and partnerships across Argentina, Peru, and Mexico.Buenbit clients to gain access to Nexo’s full suite of products, top-tier security, and personalized client care. Nexo, the premier digital asset platform with $11 billion in assets under management, today announced its acquisition of Buenbit, one of Latin America’s most trusted and fastest-growing crypto platforms. This strategic transaction marks a milestone in Nexo’s global scaling, uniting the company’s advanced liquidity infrastructure and high-yield products with Buenbit’s deep local expertise and strong customer base. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251211358777/en/ The acquisition combines Ne

Tidewater Expands Partnership with Rimini Street Following Successful Optimization of Regional ERP and Tax Software Solutions11.12.2025 15:00:00 CET | Press release

Partnership launched in Brazil to support Tidewater’s Oracle ERP paved the way for additional projects focused on improved efficiency, innovation and growth Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, managed services and Agentic AI ERP innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced the expansion of its partnership with Tidewater, the world’s largest offshore service vessel (OSV) fleet operator. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251211331615/en/ Tidewater Expands Partnership with Rimini Street Following Successful Optimization of Regional ERP and Tax Software Solutions Rimini Support™ Delivers Deep Technical Expertise and Cost Savings The relationship began in Brazil, where Tidewater selected Rimini Street to support its then current Oracle PeopleSoft ERP system. The successful engagement

Mainstay Medical Announces Coverage Recommendation from the International Society for the Advancement of Spine Surgery (ISASS) for ReActiv811.12.2025 14:30:00 CET | Press release

Mainstay Medical Holdings plc today announced that the International Society for the Advancement of Spine Surgery (ISASS) has issued recommendations and coverage criteria for the use of restorative neurostimulation for the treatment of chronic mechanical low back pain associated with multifidus muscle dysfunction. ReActiv8® restorative neurostimulation is the only therapy approved in the United States, Europe and Australia for this indication. The Statement, which affirms ISASS’ support for coverage by payers of implantable restorative neurostimulation in appropriately selected patients, was published in the December issue of the International Journal of Spine Surgery and can be accessed here: https://www.ijssurgery.com/content/early/2025/12/10/8833. The Statement reflects the growing body of clinical evidence supporting the use of ReActiv8, as well as recent developments in diagnostic coding and reimbursement pathways since ISASS’ 2023 Statement on Restorative Neurostimulation for Chr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye